Latest Protease inhibitors Stories
- In adult patients co-infected with genotype 1 (GT1) hepatitis C virus (HCV) infection and human immunodeficiency virus (HIV) type 1 infection, TURQUOISE-I demonstrated sustained virologic response
-- Studies focused on patients where there is a high unmet need today or anticipated in the near future -- BOSTON, Nov.
--Expanded indication includes both treatment-naive and treatment-experienced adult patients with or without cirrhosis-- TITUSVILLE, N.J., Nov.
Data from 25 accepted abstracts include results from: NORTH CHICAGO, Ill., Oct.
BEERSE, Belgium, September 29, 2014 /PRNewswire/ -- CHMP also issues two label extensions for darunavir Janssen-Cilag International NV (Janssen)
MarketOptimizer.org adds “PharmaPoint: Hepatitis C Virus – Global Drug Forecast and Market Analysis to 2022 – Event-Driven Update” to its store.
New Treatment Option Combining Protease Inhibitor and Boosting Agent Reduces the Number of Pills Required to Manage HIV TORONTO, Sept. 17, 2014 /CNW/ - Janssen Inc.
Two new pill-only antiviral drug regimens could provide shorter, more effective treatment options with fewer side effects for the majority of patients infected with hepatitis C, even those most difficult to treat.
The Majority of Surveyed Primary Care Physicians Expect to Refer HCV Patients to a Specialist for Care, According to Findings from Decision Resources Group BURLINGTON, Mass., June 19, 2014
NORTH CHICAGO, Ill., June 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the New Drug Application (NDA) for its investigational, all-oral, interferon-free regimen for the
- Easily ashamed, having a strong sense of shame; modest; chaste.
- Of or pertaining to the external organs of generation.